



over image: Phosphotungstic-acid-  
haematoxylin staining of systemic sclerosis  
and control placental tissue.  
See p 417.

## Editor

Core K Kvien

## Associate Editors

Francis Berenbaum  
Hans Bijlsma  
Nimitrios Boumpas  
Gerard Burmester  
Mary Crow  
Gavin McInnes

## Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
MA House  
11 Tavistock Square  
London WC1H 9JR, UK  
Tel: +44 (0)20 7383 6250  
Fax: +44 (0)20 7383 6668  
Email: ard@bmj.com  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 7.188

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2010 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission. ARD is published by BMJ Publishing Group Ltd, owned by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by printer Trend, Plymouth.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Mercury International Ltd. Periodicals postage paid at Rahway, NJ, USA. POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Mercury International Ltd, 365 Blair Road, Avenel, NJ 07001, USA.

### Editorial

- 317** Rheumatoid arthritis and pregnancy; not only for rheumatologists interested in female health issues  
*R J E M Dolhain*

### Review

- 319** Anti-endothelial cell antibodies in systemic sclerosis  
*C Mihai, J W C Tervaert*

### Recommendations

- 325** EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis  
*M J L Peters, D P M Symmons, D McCarey, B A C Dijkmans, P Nicola, T K Kvien, I B McInnes, H Haentzschel, M A Gonzalez-Gay, S Provan, A Semb, P Sidiropoulos, G Kitas, Y M Smulders, M Soubrier, Z Szekanecz, N Sattar, M T Nurmohamed*

### Clinical and epidemiological research

- 332** Postpartum onset of rheumatoid arthritis and other chronic arthritides: results from a patient register linked to a medical birth registry  
*M Wallenius, J F Skomsvoll, L M Irgens, K Å Salvesen, W Koldingsnes, K Mikkelsen, C Kaufmann, T K Kvien*
- 337** Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review  
*J J Luime, E M Colin, J M W Hazes, E Lubberts*
- 345** Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study  
*S W Syversen, G L Goll, D van der Heijde, R Landewé, B A Lie, S Ødegård, T Uhlig, P I Gaarder, T K Kvien*
- 352** Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden  
*A Gülfe, L E Kristensen, T Saxne, L T H Jacobsson, I F Petersson, P Geborek*
- 358** National cohort study of reproductive risk factors for rheumatoid arthritis in Denmark: a role for hyperemesis, gestational hypertension and pre-eclampsia?  
*K T Jørgensen, B V Pedersen, S Jacobsen, R J Biggar, M Frisch*
- 364** Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy  
*R E Alten, C Zerbini, S Jeka, F Irazoque, F Khatib, P Emery, A Bertasso, M Rabbia, J P Caulfield*

- 368** Association study of *TRAF1-C5* polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese  
*K Nishimoto, Y Kochi, K Ikari, K Yamamoto, A Suzuki, K Shimane, Y Nakamura, K Yano, N Iikuni, S Tsukahara, N Kamatani, H Okamoto, H Kaneko, Y Kawaguchi, M Hara, Y Toyama, T Horiuchi, K Tao, K Yasutomo, D Hamada, N Yasui, H Inoue, M Itakura, H Yamanaka, S Momohara*

- 374** Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice  
*R A Moore, O A Moore, S Derry, P M Peloso, A R Gamaitoni, H Wang*

- 380** Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry  
*J D Greenberg, G Reed, J M Kremer, E Tindall, A Kavanaugh, C Zheng, W Bishai, M C Hochberg, on behalf of the CORRONA Investigators*

- 387** Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?  
*A Finckh, A Ciurea, L Brulhart, B Möller, U A Walker, D Courvoisier, D Kyburz, J Dudler, C Gabay, on the behalf of the doctors of the Swiss Clinical Quality Management Programme for Rheumatoid Arthritis*

- 394** Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions  
*F Van den Bosch, B Manger, P Goupille, N McHugh, E Rødevand, P Holck, R F van Vollenhoven, M Leirisalo-Repo, O FitzGerald, M Kron, M Frank, S Kary, H Kupper*

### MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtd>

C O P E COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)

equator network

recycle  
When you have finished with this please recycle it

- 400** Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry  
*X Mariette, F Tubach, H Bagheri, M Bardet, J M Berthelot, P Gaudin, D Heresbach, A Martin, T Schaeverbeke, D Salmon, M Lemann, O Hermine, M Raphael, P Ravaud*
- 409** Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis  
*R M Thurlings, O Teng, K Vos, D M Gerlag, L Aarden, S O Stapel, J M van Laar, P P Tak, G J Wolbink*
- 413** Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial  
*J H Coombs, B J Bloom, F C Breedveld, M P Fletcher, D Gruben, J M Kremer, R Burgos-Vargas, B Wilkinson, C A F Zerbini, S H Zwillich*
- 417** A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools  
*J E Freeston, R J Wakefield, P G Conaghan, E M A Hensor, S P Stewart, P Emery*
- 420** Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy  
*Y A de Man, L E Bakker-Jonges, C M Dufour-van den Goorbergh, S P R Tillemans, H Hooijkaas, J M W Hazes, R J E M Dolhain*
- 424** Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial  
*B Fautrel, M Benhamou, M Breban, C Roy, C Lenoir, G Trape, A Baleyrier, P Ravaud, M Dougados*
- 
- Basic and translational research**
- 428** Antifibroblast antibodies from systemic sclerosis patients bind to  $\alpha$ -enolase and are associated with interstitial lung disease  
*B Terrier, M C Tamby, L Camoin, P Guilpain, A Bérezné, N Tamas, C Broussard, F Hotellier, M Humbert, G Simonneau, L Guillevin, L Mouthon*
- 434** Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events  
*E Lozano, M Segarra, M Corbera-Bellalta, A García-Martínez, G Espígol-Frigolé, A Plà-Campo, J Hernández-Rodríguez, M C Cid*
- 443** Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF $\alpha$  single-chain Fv antibody (ESBA105) designed for local therapeutic use  
*D M Urech, U Feige, S Ewert, V Schlosser, M Ottiger, K Polzer, G Schett, P Lichtlen*
- 450** Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level  
*E Jones, S M Churchman, A English, M H Buch, E A Horner, C H Burgoyne, R Reece, S Kinsey, P Emery, D McGonagle, F Ponchel*
- 458** Severe fibrotic changes and altered expression of angiogenic factors in maternal scleroderma: placental findings  
*L Ibba-Manneschi, M Manetti, A F Milia, I Miniati, G Benelli, S Guiducci, F Mecacci, G Mello, S Di Lollo, M Matucci-Cerinic*
- 462** Bcl-2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women  
*A M Delgado-Vega, J Castiblanco, L M Gómez, L-M Díaz-Gallo, A Rojas-Villarraga, J-M Anaya*
- 
- Letters**
- 466** IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease  
*L Naumann, E Feist, A Natusch, S Langen, A Krause, F Buttgerit, G-R Burmester*
- 468** Clinical evaluation of hsPR3-ANCA ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3  
*J U Holle, E Csernok, G Fredenhagen, M Backes, J P Bremer, W L Gross*
- 469** Are anti-cyclic citrullinated peptide autoantibodies seromarkers for rheumatoid vasculitis in a cohort of patients with systemic vasculitis?  
*K Laskaria, K Ahmadi-Simab, M Lamken, E Csernok, W L Gross, B Hellmich*
- 471** Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry  
*G Nocturne, M Dougados, A Constantin, C Richez, J Sellam, A Simon, D Wendling, X Mariette, J-E Gottenberg*